NRAS mutant melanoma - undrugable?

descriptionPublicationkeyboard_double_arrow_right Article 13 Apr 2013 English Publisher:Impact Journals, LLCJournal:Oncotarget, volume 4, pages 494-495 (eissn: 1949-2553,

Copyright policy )

Authors: Christian, Posch; Susana, Ortiz-Urda;

doi: 10.18632/oncotarget.970

pmid: 23660168

pmc: PMC3720596

NRAS mutant melanoma - undrugable?

- Summary
- Subjects
- Metrics

Abstract

Mutations in the three rat sarcoma (RAS) family members NRAS (neuroblastoma-RAS), HRAS (Harvey-RAS) and KRAS (Kirsten-RAS) are found in one third of human cancers. Among the first oncogenes discovered in cutaneous melanoma was NRAS, which is mutant in up to 20% of tumors causing aberrant signaling in several downstream cascades. Despite, being a highly relevant therapeutic target, design of small molecules selectively inhibiting mutant NRAS in melanoma, to date, remains an unsolved challenge. The end?

Related Organizations

University of California, San Francisco
United States

Keywords

Proto-Oncogene Proteins p21(ras), Mutation, Animals, Humans, Melanoma, Signal Transduction

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	20
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%